J.H. Whitney Equity Partners Vii, LLC

10% owner J.H. Whitney Equity Partners VII sold 5,842,240 shares of AVAH at $6.24, reducing stake 30.3% to 13.45M shares; stock down 35.5% from 52-week high.

J.H. Whitney Equity Partners VII, a 10% shareholder, divested 5,842,240 shares at $6.24 on 2026-06-03, a material 30.3% reduction of holdings, in a market where AVAH trades at $6.66 current price—35.5% below its 52-week high of $10.32. The timing context is mixed: across the insider's cross-ticker track record, a 90-day well-timed rate of 25.00% suggests poor overall sell timing, but at AVAH specifically, 1 of 4 prior sells were well-timed at the 90-day mark. The company itself shows fundamental strength—$647.9M quarterly revenue, $41.7M net income, +20.2% annual revenue growth, and a low P/E of 6.00—providing limited evidence of operational distress. The large reduction in stake may reflect portfolio rebalancing or liquidity needs by the investor rather than a directional call on the company.

J.H. Whitney Equity Partners VII sells 1,251,909 shares of AVAH at $9.00; retains 19,292,787 shares (19.29M shares)

J.H. Whitney Equity Partners VII, a 10% owner, sold 1,251,909 shares at $9.00 on 2025-10-24, reducing its stake by 6.1% while retaining a substantial 19,292,787 shares. The sale occurred near the 52-week high of $10.27 (only 4.5% below), following a robust 30-day gain of +12.1% and an exceptional 90-day gain of +145.9%. Notably, the insider executed a prior sale just three days earlier on 2025-10-21, suggesting an ongoing reduction in exposure. At this same ticker, prior sales on 2025-06-10 and 2025-05-19 posted positive 90-day returns of +58.8% and +32.1% respectively, indicating the insider sold before meaningful upside materialized; across these measurable same-ticker trades, 0 of 2 were well-timed by the 90-day standard. The company trades at a P/E of 109.00 and was unprofitable over its most recent full fiscal year, creating tension between the elevated valuation multiple and fundamental profitability—a dynamic worth monitoring alongside the insider's sequential reduction pattern.

J.H. Whitney Equity Partners VII (10% owner) sold 8,346,059 shares at $9.00 for $75.1M, cutting stake by 28.9%

A major shareholder holding 10% of Aveanna Healthcare divested 8,346,059 shares at $9.00 per share on 2025-10-21, raising $75,114,531.00 and reducing its position from 28,890,755 to 20,544,696 shares. The stock traded at $9.12 at the time of analysis and has climbed +8.7% over the 30 days following the sale. At AVAH specifically, J.H. Whitney's two prior sells (2025-06-10 and 2025-05-19) both resulted in 90-day positive returns of +58.8% and +32.1% respectively—meaning the stock rose after each prior sale, indicating the insider sold ahead of rallies rather than declines. The company's P/E of 101.33 combined with full-year unprofitability and a $1.9B market cap on $589.6M quarterly revenue signals a stretched valuation environment, framing this sale within a context of elevated equity prices.

J.H. Whitney Equity Partners VII sold 750,000 shares (2.5% of holdings) at $5.20 on 2025-06-10 for $3,900,000; stock now $5.08.

J.H. Whitney Equity Partners VII, a 10% holder of Aveanna Healthcare, sold 750,000 shares at $5.20, reducing holdings from 29,640,756 to 28,890,756 shares. The sale occurred as the stock has declined 15.3% from its 52-week high of $6.00 and 13.3% over the past 30 days, now trading at $5.08. The company's fundamentals remain strained: though revenue reached $559.2M with 6.8% annual growth, the company was unprofitable over its most recent full fiscal year and carries a P/E of 169.33 based on minimal profitability ($5.2M net income in the latest quarter). This partial liquidation by a significant stakeholder occurs within a context of weak valuation multiples and negative recent price action, but represents a modest 2.5% reduction in holdings rather than an accelerated exit.

J.H. Whitney Equity Partners VII (10% owner) sold 1,560,700 shares of AVAH at $5.36 for $8,365,352.00; retains 29,640,756 shares post-sale.

J.H. Whitney Equity Partners VII divested 1,560,700 shares at $5.36 on 2025-05-19, reducing its stake by -5.0% to 29,640,756 shares. The transaction occurred near the 52-week high range, with the current price at $5.49 showing modest downside from the sale point. Aveanna Healthcare reported negative full-year net income despite quarterly revenues of $559,224,000 and a growth rate of +6.8%, resulting in a stretched P/E of 183.00 that reflects thin profitability. The divestiture by a major 10% holder warrants observation given the company's unprofitable FY position, though the partial reduction in this investor's position—rather than a complete exit—suggests continuing confidence in the investment thesis.